BR100 Increased By (0.19%)
BR30 Decreased By (-0.02%)
KSE100 Increased By (0.19%)
KSE30 Increased By (0.21%)
AGHA 6.79 Increased By ▲ 0.11 (1.65%)
BECO 4.40 Increased By ▲ 0.03 (0.69%)
BML 56.60 Decreased By ▼ -0.72 (-1.26%)
BOP 30.45 Increased By ▲ 0.10 (0.33%)
CNERGY 13.14 Increased By ▲ 0.02 (0.15%)
CSIL 5.40 Decreased By ▼ -0.01 (-0.18%)
FCCL 52.95 Increased By ▲ 0.16 (0.3%)
FFL 14.84 Increased By ▲ 0.12 (0.82%)
FNEL 1.12 No Change ▼ 0.00 (0%)
KEL 6.13 Increased By ▲ 0.04 (0.66%)
KOSM 5.93 Increased By ▲ 0.20 (3.49%)
LOTCHEM 26.56 Increased By ▲ 0.10 (0.38%)
MLCF 93.64 Increased By ▲ 0.48 (0.52%)
NBP 165.00 Increased By ▲ 0.34 (0.21%)
NCPL 55.72 Increased By ▲ 0.06 (0.11%)
NPL 61.09 Decreased By ▼ -0.07 (-0.11%)
OGDC 315.70 Decreased By ▼ -1.03 (-0.33%)
PACE 9.94 Increased By ▲ 0.07 (0.71%)
PAEL 35.64 Increased By ▲ 0.01 (0.03%)
PIBTL 14.99 Increased By ▲ 0.31 (2.11%)
PPL 225.50 Decreased By ▼ -1.41 (-0.62%)
PRL 93.25 Increased By ▲ 0.23 (0.25%)
PTC 60.40 Increased By ▲ 0.14 (0.23%)
SSGC 23.84 Increased By ▲ 0.03 (0.13%)
TBL 8.83 Increased By ▲ 0.08 (0.91%)
TELE 7.86 Increased By ▲ 0.06 (0.77%)
TPL 22.62 Increased By ▲ 0.27 (1.21%)
TPLP 12.96 Decreased By ▼ -0.01 (-0.08%)
TREET 22.30 Increased By ▲ 0.14 (0.63%)
TRG 56.77 Increased By ▲ 0.21 (0.37%)
By

NEW YORK: Pfizer Inc and Moderna Inc have raised the prices of their COVID-19 vaccines in their latest European Union supply contracts, the Financial Times reported on Sunday. The new price for the Pfizer shot was 19.50 euros ($23.15) against 15.50 euros previously, the newspaper said, citing portions of the contracts seen.

The price of a Moderna vaccine was $25.50 a dose, the contracts show, up from about 19 euros in the first procurement deal but lower than the previously agreed $28.50 because the order had grown, the report said, citing one official close to the matter.

The European Commission said on Tuesday that the EU is on course to hit a target of fully vaccinating at least 70% of the adult population by the end of the summer.

In May, the EU said it expects to have received more than a billion doses of vaccines by the end of September from four drugmakers. Pfizer and Moderna were not immediately available for comment to Reuters.

Comments

Comments are closed for this article.